Tatva Chintan Pharma Chem Limited (TATVA) Fair Value & Analysis
Basic Materials · IN · Market cap ₹29.2B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +2.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹927.13 – ₹1,589 · fair‑value band ₹229.22 – ₹321.57 · the ₹1,250 price screens above the ₹274.79 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tatva Chintan Pharma Chem Limited (TATVA) currently trades at ₹1,250, while our model-based Fair Value estimate is ₹274.79 — implying the stock looks roughly 78.0% overvalued today. We read business quality at 52/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Tatva Chintan Pharma Chem Limited generated revenue of ₹5.1B at a net margin of 8.3%. Revenue grew 24.4% year over year. It earns a return on equity of 5.5%. Net debt stands at ₹1.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tatva Chintan Pharma Chem Limited reported revenue of ₹5.1B in FY2026 versus ₹4.3B in FY2022, a compound +3.9%/yr. Reported net income was ₹421M in FY2026, compounding −18.6%/yr from FY2022.
Is TATVA fairly valued? → Check now
Similar stocks
6 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $509.16 | $159.69 | -69% |
| L'Air Liquide S.A AIQUY | $37.93 | $15.46 | -59% |
| Air Products and Chemicals, Inc A1PD34 | R$360.05 | R$108.63 | -70% |
| Intercontinental Exchange, Inc I1CE34 | R$334.47 | R$67.12 | -80% |
| Wanhua Chemical Group 600309 | ¥74.30 | ¥68.03 | -8% |
| Asian Paints Limited ASIANPAINT | ₹2,715 | ₹655.71 | -76% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Tatva Chintan Pharma Chem Limited (TATVA) undervalued?
What is the fair value of TATVA?
What is the quality score of TATVA?
What is the revenue of Tatva Chintan Pharma Chem Limited (TATVA)?
What is the net profit margin of TATVA?
Does Tatva Chintan Pharma Chem Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.